We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Single-Use Test Strip to Revolutionize Disease Diagnosis

By LabMedica International staff writers
Posted on 09 Feb 2026

Early detection is critical for diseases such as cancer, but many biological warning signals circulate in the blood at levels too low to be reliably detected. More...

MicroRNAs are among the most promising early biomarkers, yet their extremely low concentrations often place them beyond the reach of standard laboratory tests. This diagnostic gap limits early intervention and timely treatment decisions. A new single-use test strip now demonstrates that these elusive molecular signals can be detected quickly and sensitively without complex lab infrastructure.

Inspired by glucose test strips, the biosensor developed by researchers at La Trobe University (Victoria, Australia) uses an electrochemical readout to detect disease-associated microRNAs in blood plasma. The key innovation lies in integrating a specialized enzyme that dramatically amplifies subtle electrical changes generated when microRNAs bind to the sensor surface.

When a biological sample is added to the strip, the presence of a target microRNA alters the electrical signal produced by the sensor. The enzyme enhances this response, allowing the system to detect microRNAs at concentrations up to a trillion times lower than glucose levels. This sensitivity surpasses many existing molecular techniques and enables detection even when biomarkers are present in extremely small amounts.

The biosensor was validated using blood plasma samples, where it successfully detected microRNAs at concentrations up to 1,000 times lower than previously achievable with similar strip-based technologies. The results, published in Small, show that enzyme amplification enables robust and reproducible detection of microRNAs that are typically difficult to measure using standard PCR-based assays.

This technology opens the door to point-of-need diagnostics that do not rely on centralized laboratories or highly trained personnel. The researchers envision the test strip being incorporated into portable devices for routine disease screening, monitoring treatment response, and enabling earlier diagnosis of conditions such as cancer. Further development will focus on expanding the range of detectable microRNAs and translating the technology into clinical settings.

“It is exciting to be one step closer to disease diagnosis and monitoring that is truly point-of-need: affordable, convenient, accessible, and effective,” said Distinguished Professor Brian Abbey, Senior Researcher, La Trobe University, and co-developer of the biosensor.

Related Links:
La Trobe University


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The study identified a distinct immune signature associated with treatment-resistant myasthenia gravis (Dodd, Katherine C. et al., Med (2026). DOI: 10.1016/j.medj.2025.100987)

Immune Signature Identified in Treatment-Resistant Myasthenia Gravis

Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.